LENZ Therapeutics, Inc. - 8-K Filing
LENZ Therapeutics announces strategic reorganization involving 75% headcount reduction and leadership transition as CEO Evert Schimmelpennink resigns. (Items: 2.02 Results of Operations and Financial Condition, 2.05 Costs Associated with Exit or Disposal Activities, 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Offi, 9.01 Financial Statements and Exhibits)
Tickers: $LENZ